Vanguard Group Inc Savara Inc Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Savara Inc stock. As of the latest transaction made, Vanguard Group Inc holds 8,309,970 shares of SVRA stock, worth $20.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,309,970
Previous 7,944,011
4.61%
Holding current value
$20.7 Million
Previous $33.7 Million
24.26%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SVRA
# of Institutions
141Shares Held
158MCall Options Held
55.6KPut Options Held
600-
Nea Management Company, LLC Timonium, MD24.5MShares$60.9 Million5.37% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$36.3 Million12.07% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$30.8 Million6.2% of portfolio
-
Vestal Point Capital, LP New York, NY10.8MShares$26.8 Million1.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.66MShares$21.6 Million1.59% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $284M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.